These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 36125928)
1. Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy. Tanaka N; Nakai Y; Asakawa I; Yamaki K; Miyake M; Hori S; Owari T; Fujii T; Fujimoto K Int J Urol; 2022 Dec; 29(12):1560-1568. PubMed ID: 36125928 [TBL] [Abstract][Full Text] [Related]
2. Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy. Enei Y; Urabe F; Miki K; Suzuki H; Iwatani K; Tashiro K; Tsuzuki S; Furuta A; Sasaki T; Sato S; Takahashi H; Aoki M; Kimura T Anticancer Res; 2023 Jul; 43(7):3159-3166. PubMed ID: 37351978 [TBL] [Abstract][Full Text] [Related]
3. The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. Tanaka N; Asakawa I; Katayama E; Hirayama A; Hasegawa M; Konishi N; Fujimoto K Radiat Oncol; 2014 May; 9():107. PubMed ID: 24885896 [TBL] [Abstract][Full Text] [Related]
4. Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer? Tabata R; Kimura T; Kuruma H; Sasaki H; Kido M; Miki K; Takahashi H; Aoki M; Egawa S Cancer Med; 2016 Sep; 5(9):2314-22. PubMed ID: 27456710 [TBL] [Abstract][Full Text] [Related]
5. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855 [TBL] [Abstract][Full Text] [Related]
6. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027 [TBL] [Abstract][Full Text] [Related]
7. Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy. Niwa N; Matsumoto K; Nishiyama T; Yagi Y; Ozu C; Nakamura K; Saito S; Oya M Brachytherapy; 2018; 17(6):899-905. PubMed ID: 30245170 [TBL] [Abstract][Full Text] [Related]
8. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy. Pickles T; Morris WJ; Keyes M Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014 [TBL] [Abstract][Full Text] [Related]
9. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. Lazarev S; Thompson MR; Stone NN; Stock RG BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928 [TBL] [Abstract][Full Text] [Related]
10. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Baumann BC; Baumann JC; Christodouleas JP; Soffen E Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422 [TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537 [TBL] [Abstract][Full Text] [Related]
12. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. Stock RG; Buckstein M; Liu JT; Stone NN BJU Int; 2013 Jul; 112(2):E44-50. PubMed ID: 23773225 [TBL] [Abstract][Full Text] [Related]
13. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
14. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107 [TBL] [Abstract][Full Text] [Related]
15. After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis. Oh J; Morris WJ; Spadinger I; Tyldesley S; Keyes M; Halperin R; Crook J; Lapointe V; Pickles T Brachytherapy; 2022; 21(5):605-616. PubMed ID: 35729030 [TBL] [Abstract][Full Text] [Related]
16. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer. Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400 [TBL] [Abstract][Full Text] [Related]
19. Mid-term outcome of permanent prostate iodine-125 brachytherapy in Japanese patients. Kimura T; Kido M; Miki K; Yamamoto T; Sasaki H; Kuruma H; Hayashi N; Takahashi H; Aoki M; Egawa S Int J Urol; 2014 May; 21(5):473-8. PubMed ID: 24256329 [TBL] [Abstract][Full Text] [Related]
20. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Tsumura H; Tanaka N; Oguchi T; Owari T; Nakai Y; Asakawa I; Iijima K; Kato H; Hashida I; Tabata KI; Satoh T; Ishiyama H Radiat Oncol; 2022 Apr; 17(1):71. PubMed ID: 35410307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]